Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis

Kinder, Brent W.; Brown, Kevin K.; McCormack, Francis X.; Ix, Joachim H.; Kervitsky, Alma; Schwarz, Marvin I.; King, Talmadge E.

doi:10.1378/chest.08-2209

Cited by 190 publications

(126 citation statements)

References 26 publications

(42 reference statements)

Supporting

Mentioning

121

Contrasting

Unclassified

Order By: Relevance

“…Future studies should also consider whether sLOXL2, along with other promising prognostic IPF biomarkers (e.g. matrix metalloproteinase (MMP)1, MMP7, KL-6, periostin, surfactant protein-A and D, CC chemokine ligand 18, vascular endothelial growth factor and YKL-40) [19][20][21][22][23][24][25][26][27][28][29], as well as prognostic scores [30,31] and radiological modalities [32], might have prognostic value for helping physicians and patients anticipate the patient's IPF disease progression. This might include evaluation of serially collected sLOXL2 levels and their relationship to IPF acute exacerbations, which represent a terminal event for many IPF patients [33].…”

Section: Discussionmentioning

confidence: 99%

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Chien¹,

Richards

Gibson

et al. 2013

European Respiratory Journal

134

View full text Add to dashboard Cite

We evaluated whether lysyl oxidase-like 2 (LOXL2), which promotes cross-linking of collagen in pathological stroma, was detectable in serum from idiopathic pulmonary fibrosis (IPF) patients, and assessed its relationship with IPF disease progression.Patients from the ARTEMIS-IPF (n569) and the Genomic and Proteomic Analysis of Disease Progression in IPF (GAP) (n5104) studies were analysed. Baseline serum LOXL2 (sLOXL2) levels were compared with baseline clinical and physiological surrogates of disease severity, and the association with IPF disease progression was assessed using a classification and regression tree (CART) method. sLOXL2 correlated weakly with forced vital capacity and carbon monoxide diffusion capacity (r -0.24-0.05) in both cohorts. CART-determined thresholds were similar: ARTEMIS-IPF 800 pg?mL -1 and GAP 700 pg?mL -1. In ARTEMIS-IPF, higher sLOXL2 (.800 pg?mL -1 ) was associated with increased risk for disease progression (hazard ratio (HR) 5.41, 95% CI 1.65-17.73). Among GAP subjects with baseline spirometric data (n570), higher sLOXL2 levels (.700 pg?mL -1 ) were associated with more disease progression events (HR 1.78, 95% CI 1.01-3.11). Among all GAP subjects, higher sLOXL2 levels were associated with increased risk for mortality (HR 2.28, 95% CI 1.18-4.38).These results suggest that higher sLOXL2 levels are associated with increased risk for IPF disease progression. However, due to multiple limitations, these results require validation. Clinical trial: This study is registered at www.ClinicalTrials.gov with identifier number NCT00768300 and NCT 00373841.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Chien¹,

Richards

Gibson

et al. 2013

European Respiratory Journal

134

View full text Add to dashboard Cite

show abstract

“…In a group of seven asymptomatic patients with signs of early pulmonary fibrosis in the posterior subpleural region on CT scanning, increased levels of serum SP-A and SP-D were detected [44] Kinder et al found that high levels of SP-A at time of initial diagnosis was a strong predictor of mortality in a well defined group of 82 patients with IPF. Furthermore, a model using baseline serum SP-A and SP-D provided substantial additive predictive value and was superior to a model based on clinical parameters alone [45].…”

Section: Kl-6mentioning

confidence: 92%

Serum biomarkers in idiopathic pulmonary fibrosis

Blink

Wijsenbeek

Hoogsteden

2010

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…They have also been shown to have prognostic value for mortality in IPF; concentrations of SP-A may indicate a more destructive phenotype, and concentrations of SP-D appear to relate to the extent of deterioration in pulmonary function per year and the degree of radiographic abnormality. [45][46][47][48] Kinder and colleagues 46 demonstrated that the addition of SP-A and SP-D to an IPF clinical prediction model improved performance in the prediction of 1-year mortality.…”

Section: Sp-a and Sp-dmentioning

confidence: 99%

“…Assessment of COPD exacerbations relies mostly on clinical 43,44,[58][59][60] ; MMP 5 matrix metalloproteinase 11,40,[49][50][51]53 ; MPIF-1 5 myeloid progenitor inhibitory factor-1 61 ; S100A12 53 ; SP 5 surfactant protein 10,[34][35][36][37]46,48,62,[58][59][60] ; TNF-a 5 tumor necrosis factor-a 10,26 ; TNFRSF1A 5 tumor necrosis factor receptor superfam ily, member 1A 51 ; VCAM-1 5 vascular cell adhesion moledule-1 53 ; YKL-40. 56 to identify clinical phenotypes such as rapid decliners and frequent exacerbators.…”

Section: Biomarkers Of Copd and Ipf Exacerbationsmentioning

confidence: 99%

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Doyle

Pinto-Plata

Morse

et al. 2012

Chest

View full text Add to dashboard Cite

Recent advances in the fi eld of clinical biomarkers suggest that quantifi cation of serum proteins could play an important role in the diagnosis, classifi cation, prognosis, and treatment response of smoking-related parenchymal lung diseases. COPD and idiopathic pulmonary fi brosis (IPF), two common chronic progressive parenchymal lung diseases, share cigarette smoke exposure as a common dominant risk factor for their development. We have recently shown that COPD and interstitial lung disease may represent distinct outcomes of chronic tobacco use, whereas others have demonstrated that both diseases coexist in some individuals . In this perspective, we examine the potential role of peripheral blood biomarkers in predicting which individuals will develop COPD or IPF, as well as their usefulness in tracking disease progression and exacerbations. Additionally, given the current lack of sensitive and effective metrics to determine an individual's response to treatment, we evaluate the potential role of biomarkers as surrogate markers of clinical outcomes. Finally, we examine the possibility that changes in levels of select protein biomarkers can provide mechanistic insight into the common origins and unique individual susceptibilities that lead to the development of smoking-related parenchymal lung diseases. This discussion is framed by a consideration of the properties of ideal biomarkers for different clinical and research purposes and the best uses for those biomarkers that have already been proposed and investigated.CHEST 2012; 142(4):1027-1034Abbreviations: BODE 5 BMI, airfl ow obstruction, dyspnea, and exercise capacity; CCL-18 5 CC-chemokine ligand-18; CRP 5 C-reactive protein; IPF 5 idiopathic pulmonary fi brosis; KL-6 5 Krebs von den Lungen-6; MMP 5 matrix metalloproteinase; SP 5 surfactant protein; TNF-a 5 tumor necrosis factor-a

show abstract

Serum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis

Abstract: Increased serum SP-A level is a strong and independent predictor of early mortality among patients with IPF. A prediction model containing SP-A and SP-D was substantially superior to a model with clinical predictors alone.

Cited by 190 publications

References 26 publications

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression

Serum biomarkers in idiopathic pulmonary fibrosis

The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases

Contact Info

Product

Resources

About